Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers.

Autor:	Kegyes D; Department of Hematology/Medfuture Research Center for Advanced Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Milea PA; Department of Hematology/Medfuture Research Center for Advanced Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Mazga AI; Department of Hematology/Medfuture Research Center for Advanced Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Tigu AB; Department of Hematology/Medfuture Research Center for Advanced Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Nistor M; Department of Hematology/Medfuture Research Center for Advanced Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Cenariu D; Department of Hematology/Medfuture Research Center for Advanced Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Tomai R; Department of Hematology, Ion Chiricuta Cancer Center, Cluj-Napoca, Romania., Buruiana S; Department of Hematology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova., Einsele H; Department of Hematology/Medfuture Research Center for Advanced Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.; Department of Internal Medicine II, Hematology, University Hospital Würzburg, Würzburg, Germany., Daniela Tănase A; Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania., Tomuleasa C; Department of Hematology/Medfuture Research Center for Advanced Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.; Department of Hematology, Ion Chiricuta Cancer Center, Cluj-Napoca, Romania.; Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Jazyk:	angličtina
Zdroj:	Expert opinion on therapeutic targets [Expert Opin Ther Targets] 2024 Sep; Vol. 28 (9), pp. 779-787. Date of Electronic Publication: 2024 Sep 05.
DOI:	10.1080/14728222.2024.2400075
Abstrakt:	Introduction: The bone marrow microenvironment (BME) is critical for healthy hematopoiesis and is often disrupted in hematologic malignancies. Tumor-associated macrophages (TAMs) are a major cell type in the tumor microenvironment (TME) and play a significant role in tumor growth and progression. Targeting TAMs and modulating their polarization is a promising strategy for cancer therapy. Areas Covered: In this review, we discuss the importance of TME and different multiple possible targets to modulate immunosuppressive TAMs such as: CD123, Sphingosine 1-Phosphate Receptors, CD19/CD1d, CCR4/CCL22, CSF1R (CD115), CD24, CD40, B7 family proteins, MARCO, CD47, CD163, CD204, CD206 and folate receptors. Expert Opinion: Innovative approaches to combat the immunosuppressive milieu of the tumor microenvironment in hematologic malignancies are of high clinical significance and may lead to increased survival, improved quality of life, and decreased toxicity of cancer therapies. Standard procedures will likely involve a combination of CAR T/NK-cell therapies with other treatments, leading to more comprehensive cancer care.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu